Figure 8.

Suppressed activation of caspase-8, -9, -3, and -7 by caspase inhibitors in RL95-2 endometrial cancer cells following combined treatment with DHA and triacsin C. Cells were exposed to 125 μM DHA and 5 μM triacsin C for 14 h in the absence or presence of zVAD-FMK (pan caspase inhibitor), DEVE-CHO (caspase-3/-7 inhibitor), IETD-CHO (caspase-8 inhibitor), LEHD-CHO (caspase-9 inhibitor), or IETD plus LEHD, respectively. Changes in caspases by caspase inhibitors in RL95-2 cells following exposure to DHA and triacsin C are shown by western blot analyses for caspase-8, -9, -3, and -7, and PARP cleavage. Equal amounts of protein (30 μg) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblotted using a cleaved form-specific antibody for caspase-8, -9 -3, and -7, and PARP antibody. Actin expression was examined as a loading control

“-” – DHA and triacsin C without treatment, “+” – 125 μM DHA and 5 μM triacsin C treatment for 14 h.